<?xml version="1.0" encoding="UTF-8"?>
<rss version="2.0" xmlns:media="http://search.yahoo.com/mrss/">
  <channel>
    <title>Digital health</title>
    <description>
      <![CDATA[]]>
    </description>
    <link>https://www.bioworld.com/rss</link>
    <language>en-us</language>
    <item>
      <title>Radnet acquires Gleamer for up to €230M</title>
      <description>
        <![CDATA[Radnet Inc. acquired Gleamer SAS for up to €230 million (US$267 million) as it continues to expand its position across imaging and acute diagnostic care, while accelerating its move toward AI-powered automated diagnostics. Gleamer will be integrated into Radnet’s subsidiary, Deephealth Inc., strengthening its imaging portfolio, and positioning the company as the world’s largest provider of radiology clinical AI solutions.]]>
      </description>
      <guid>http://www.bioworld.com/articles/729287</guid>
      <pubDate>Tue, 03 Mar 2026 12:00:00 -0500</pubDate>
      <link>https://www.bioworld.com/articles/729287-radnet-acquires-gleamer-for-up-to-230m</link>
      <media:content url="https://www.bioworld.com/ext/resources/Stock-images/Deals-and-MAs/Digital-handshake.webp?t=1683126686" type="image/jpeg" medium="image" fileSize="453851">
        <media:title type="plain">Digital handshake </media:title>
      </media:content>
    </item>
    <item>
      <title>FDA’s new general wellness guidance is no dramatic overhaul</title>
      <description>
        <![CDATA[The U.S. FDA’s reissuance of the 2019 guidance for general wellness products seems to carve out new territory for makers of wearables that make modest claims regarding health, but anyone who was expecting a clear break with the 2019 version of the guidance was almost certainly disappointed.]]>
      </description>
      <guid>http://www.bioworld.com/articles/727595</guid>
      <pubDate>Thu, 08 Jan 2026 11:00:00 -0500</pubDate>
      <link>https://www.bioworld.com/articles/727595-fdas-new-general-wellness-guidance-is-no-dramatic-overhaul</link>
      <media:content url="https://www.bioworld.com/ext/resources/Stock-images/Regulatory/Regulatory-icons.webp?t=1680727865" type="image/png" medium="image" fileSize="30365">
        <media:title type="plain">Regulatory icons </media:title>
      </media:content>
    </item>
    <item>
      <title>Crescom wins FDA clearance for bone analysis</title>
      <description>
        <![CDATA[Crescom Co. Ltd., an AI musculoskeletal imaging company, gained U.S. FDA 510(k) clearance Dec. 24 for MediAI-BA, its AI-powered pediatric and adolescent bone age analysis software.
Classified as a class II medical device, MediAI-BA evaluates bone age and suggests predicted adult height based on growth plate status assessed by hand and wrist X-ray imaging. Prior clinical trial results demonstrated MediAI-BA had specialist-level accuracy, recording a mean absolute deviation (MAD) of 0.39 years.]]>
      </description>
      <guid>http://www.bioworld.com/articles/727223</guid>
      <pubDate>Wed, 24 Dec 2025 11:00:00 -0500</pubDate>
      <link>https://www.bioworld.com/articles/727223-crescom-wins-fda-clearance-for-bone-analysis</link>
      <media:content url="https://www.bioworld.com/ext/resources/BMT-source/2025/Crescom-MediAI-BA-24dec25.webp?t=1766601685" type="image/jpeg" medium="image" fileSize="71686">
        <media:title type="plain">Crescom MediAI-BA</media:title>
        <media:description type="plain">Crescom MediAI-BA bone age analysis software. Credit: Crescom</media:description>
      </media:content>
    </item>
    <item>
      <title>Acryl raises $28M IPO, aiming to bridge medical divide with AI</title>
      <description>
        <![CDATA[Acryl Inc. debuted on South Korea’s Kosdaq Dec. 16, raising ₩42.12 billion ($28.5 million) in an IPO. Shares (KOSDAQ:0007C0) closed at ₩67,000 on the first day, up 243.5% from its offering price, before closing 30% down on Dec. 17 at ₩47,500. Seoul, South Korea-based Acryl sold 2.16 million shares priced at ₩19,500 each. Notably, Acryl won South Korea Ministry of Food and Drug Safety approval of Acryl-D01 software in December 2024, making it the country’s first AI-based digital therapeutic solution for depression screening and diagnosis. The generative AI-based medical software is cleared to analyze patient interviews and medical records and provide a probability score for clinical depression.]]>
      </description>
      <guid>http://www.bioworld.com/articles/727084</guid>
      <pubDate>Wed, 17 Dec 2025 11:00:00 -0500</pubDate>
      <link>https://www.bioworld.com/articles/727084-acryl-raises-28m-ipo-aiming-to-bridge-medical-divide-with-ai</link>
      <media:content url="https://www.bioworld.com/ext/resources/Stock-images/Money/IPO-stock-market-ticker.webp?t=1596572091" type="image/png" medium="image" fileSize="341793">
        <media:title type="plain">IPO stock market ticker</media:title>
      </media:content>
    </item>
    <item>
      <title>Cha Group to Acquire Majority Stake in Kakao Healthcare</title>
      <description>
        <![CDATA[Kakao Healthcare Corp. plans to secure ₩100 billion (US$68 million) through two investment deals with Cha Biomedical Group and outside investors by early next year. The transactions, expected to close by the first quarter of 2026, will make Cha the controlling shareholder of Kakao Healthcare with a 43.08% stake. Kakao Corp., the parent company, will hold 29.99%, and external investors will own 26.93%.]]>
      </description>
      <guid>http://www.bioworld.com/articles/726394</guid>
      <pubDate>Tue, 25 Nov 2025 11:00:00 -0500</pubDate>
      <link>https://www.bioworld.com/articles/726394-cha-group-to-acquire-majority-stake-in-kakao-healthcare</link>
      <media:content url="https://www.bioworld.com/ext/resources/Stock-images/Money/South-Korean-won3.webp?t=1588792152" type="image/png" medium="image" fileSize="205806">
        <media:title type="plain">South Korean won</media:title>
      </media:content>
    </item>
    <item>
      <title>Minze, Medtronic partner on overactive bladder care in EMEA</title>
      <description>
        <![CDATA[Minze Health NV signed a three-year agreement with Medtronic plc to bring its Minze Diary Pod, an app-controlled automated urine collection device, to markets across the EMEA region. The partnership aims to enhance the support services available for patients with overactive bladder receiving sacral neuromodulation therapy with Medtronic’s Interstim system.]]>
      </description>
      <guid>http://www.bioworld.com/articles/725972</guid>
      <pubDate>Wed, 12 Nov 2025 11:00:00 -0500</pubDate>
      <link>https://www.bioworld.com/articles/725972-minze-medtronic-partner-on-overactive-bladder-care-in-emea</link>
      <media:content url="https://www.bioworld.com/ext/resources/Stock-images/Therapeutic-topics/Cancer/Bladder-cancer-illustration.webp?t=1744210757" type="image/jpeg" medium="image" fileSize="76477">
        <media:title type="plain">Illustration showing cross-section of bladder with tumor on bladder wall</media:title>
      </media:content>
    </item>
    <item>
      <title>South Korea ramping up investment in medical device R&amp;D</title>
      <description>
        <![CDATA[A four-way interagency initiative in South Korea, started in 2020, is working to bolster funding for the local medical device industry and grow homegrown devices for the global market. ]]>
      </description>
      <guid>http://www.bioworld.com/articles/725959</guid>
      <pubDate>Tue, 11 Nov 2025 11:00:00 -0500</pubDate>
      <link>https://www.bioworld.com/articles/725959-south-korea-ramping-up-investment-in-medical-device-r-and-d</link>
      <media:content url="https://www.bioworld.com/ext/resources/Stock-images/Geographic-regions/Asia/South-Korea-flag-with-stock-chart-gold-coins.webp?t=1749843713" type="image/jpeg" medium="image" fileSize="608352">
        <media:title type="plain">South Korea flag with stock chart, gold coins</media:title>
      </media:content>
    </item>
    <item>
      <title>SK Bio, Eurofarma launch Mentis Care for digital epilepsy care</title>
      <description>
        <![CDATA[SK Biopharmaceuticals Co. Ltd. and Eurofarma Laboratórios SA launched a new joint venture (JV) called Mentis Care Inc. Oct. 21, dedicated to developing an AI-powered platform for epilepsy management.]]>
      </description>
      <guid>http://www.bioworld.com/articles/725433</guid>
      <pubDate>Wed, 22 Oct 2025 12:00:00 -0400</pubDate>
      <link>https://www.bioworld.com/articles/725433-sk-bio-eurofarma-launch-mentis-care-for-digital-epilepsy-care</link>
      <media:content url="https://www.bioworld.com/ext/resources/BMT-source/2025/SK-Biopharm-21oct25.webp?t=1761070694" type="image/jpeg" medium="image" fileSize="448559">
        <media:title type="plain">SK Biopharm execs</media:title>
        <media:description type="plain">Executives – including SK Biopharm CEO Lee Dong-hoon (third from left); Hassan Kotob, CEO of Mentis Care (third from right) and Rodrigo Pereira, global executive director at Eurofarma (first on left) – celebrate the launch of Mentis Care in Toronto Oct. 20.</media:description>
      </media:content>
    </item>
    <item>
      <title>SK Bio, Eurofarma launch Mentis Care for digital epilepsy care</title>
      <description>
        <![CDATA[SK Biopharmaceuticals Co. Ltd. and Eurofarma Laboratórios SA launched a new joint venture called Mentis Care Inc. Oct. 21, dedicated to developing an AI-powered platform for epilepsy management.]]>
      </description>
      <guid>http://www.bioworld.com/articles/725152</guid>
      <pubDate>Tue, 21 Oct 2025 12:00:00 -0400</pubDate>
      <link>https://www.bioworld.com/articles/725152-sk-bio-eurofarma-launch-mentis-care-for-digital-epilepsy-care</link>
      <media:content url="https://www.bioworld.com/ext/resources/BMT-source/2025/SK-Biopharm-21oct25.webp?t=1761070694" type="image/jpeg" medium="image" fileSize="448559">
        <media:title type="plain">SK Biopharm execs</media:title>
        <media:description type="plain">Executives – including SK Biopharm CEO Lee Dong-hoon (third from left); Hassan Kotob, CEO of Mentis Care (third from right) and Rodrigo Pereira, global executive director at Eurofarma (first on left) – celebrate the launch of Mentis Care in Toronto Oct. 20.</media:description>
      </media:content>
    </item>
    <item>
      <title>Pomdoctor closes $20M IPO to grow mobile health platform in China</title>
      <description>
        <![CDATA[Pomdoctor Ltd. raised $20 million through a Nasdaq IPO on Oct. 8, with the funds geared to expand its mobile health platform for chronic diseases in China.]]>
      </description>
      <guid>http://www.bioworld.com/articles/724830</guid>
      <pubDate>Fri, 10 Oct 2025 12:00:00 -0400</pubDate>
      <link>https://www.bioworld.com/articles/724830-pomdoctor-closes-20m-ipo-to-grow-mobile-health-platform-in-china</link>
      <media:content url="https://www.bioworld.com/ext/resources/BMT-source/2025/Pomdoctor-10oct25.webp?t=1760130283" type="image/jpeg" medium="image" fileSize="248601">
        <media:title type="plain">Pomdoctor</media:title>
        <media:description type="plain">Pomdoctor</media:description>
      </media:content>
    </item>
    <item>
      <title>FDA, IMDRF at loggerheads over scope of PCCP guidances</title>
      <description>
        <![CDATA[The International Medical Device Regulators Forum (IMDRF) has issued a draft guidance for predetermined change control plans for software as a medical device. The problem for advocates of regulatory harmonization is that the IMDRF draft overlaps awkwardly with the FDA’s approach, which has issued separate policies for the AI subset of device software functions and a separate guidance for all other devices, including non-AI software.]]>
      </description>
      <guid>http://www.bioworld.com/articles/724820</guid>
      <pubDate>Thu, 09 Oct 2025 12:00:00 -0400</pubDate>
      <link>https://www.bioworld.com/articles/724820-fda-imdrf-at-loggerheads-over-scope-of-pccp-guidances</link>
      <media:content url="https://www.bioworld.com/ext/resources/Stock-images/Regulatory/international-standards-ISO.webp?t=1623704519" type="image/png" medium="image" fileSize="1662175">
        <media:title type="plain">ISO icons</media:title>
      </media:content>
    </item>
    <item>
      <title>Philips rebuilds trust while driving APAC transformation</title>
      <description>
        <![CDATA[As Royal Philips NV works to rebuild trust after a global device recall, it is investing in new models of access, affordability, and technology to close gaps in sleep apnea diagnosis and therapy across Asia.]]>
      </description>
      <guid>http://www.bioworld.com/articles/724231</guid>
      <pubDate>Wed, 24 Sep 2025 12:00:00 -0400</pubDate>
      <link>https://www.bioworld.com/articles/724231-philips-rebuilds-trust-while-driving-apac-transformation</link>
      <media:content url="https://www.bioworld.com/ext/resources/Stock-images/Geographic-regions/Asia/APAC.webp?t=1588614533" type="image/png" medium="image" fileSize="522943">
        <media:title type="plain">Globe showing Asia-Pacific region</media:title>
      </media:content>
    </item>
    <item>
      <title>Alimetry brings first wearable gut diagnostic to market</title>
      <description>
        <![CDATA[Alimetry Ltd. is making waves far beyond its home market with its first-in-class wearable Gastric Alimetry device that measures gut function – an area long considered a black box in gastroenterology.]]>
      </description>
      <guid>http://www.bioworld.com/articles/724109</guid>
      <pubDate>Wed, 17 Sep 2025 12:00:00 -0400</pubDate>
      <link>https://www.bioworld.com/articles/724109-alimetry-brings-first-wearable-gut-diagnostic-to-market</link>
      <media:content url="https://www.bioworld.com/ext/resources/BMT-source/2025/Gastric-Alimetry-device-17sept25.webp?t=1758133480" type="image/jpeg" medium="image" fileSize="377795">
        <media:title type="plain">Gastric Alimetry</media:title>
        <media:description type="plain">The Gastric Alimetry device is like an ECG for the gut. Credit: Alimetry</media:description>
      </media:content>
    </item>
    <item>
      <title>Goodpath accelerates AI development following $18M series A</title>
      <author>holland.johnson@clarivate.com</author>
      <description>
        <![CDATA[Goodpath Inc., a virtual provider of whole-person care for chronic conditions, raised $18 million in series A financing, led by Massmutual Ventures with participation from Healthy Ventures and current investors. ]]>
      </description>
      <guid>http://www.bioworld.com/articles/723746</guid>
      <pubDate>Fri, 12 Sep 2025 12:00:00 -0400</pubDate>
      <link>https://www.bioworld.com/articles/723746-goodpath-accelerates-ai-development-following-18m-series-a</link>
      <media:content url="https://www.bioworld.com/ext/resources/Stock-images/Money/Venture-funding.webp?t=1588343882" type="image/png" medium="image" fileSize="186259">
        <media:title type="plain">Gold coins and sprouting plants</media:title>
      </media:content>
    </item>
    <item>
      <title>Eko’s AI-stethoscope more than doubles heart disease detection</title>
      <description>
        <![CDATA[In a real-world study, Eko Health Inc.’s AI-enabled digital stethoscope dramatically increased detection rates for atrial fibrillation, heart failure and valvular heart disease in primary care settings. Researchers from Imperial College London presented results from the study at the European Society of Cardiology in Madrid. ]]>
      </description>
      <guid>http://www.bioworld.com/articles/723737</guid>
      <pubDate>Thu, 11 Sep 2025 12:00:00 -0400</pubDate>
      <link>https://www.bioworld.com/articles/723737-ekos-ai-stethoscope-more-than-doubles-heart-disease-detection</link>
      <media:content url="https://www.bioworld.com/ext/resources/BMT-source/2025/eko-health-stethescope-11sept25.webp?t=1757625826" type="image/jpeg" medium="image" fileSize="165628">
        <media:title type="plain">Eko Health AI stethescope</media:title>
        <media:description type="plain">Eko Health Inc. Duo stethoscope. Credit: Courtesy Eko Health</media:description>
      </media:content>
    </item>
    <item>
      <title>Opportunities remain in the EU for med tech despite US shift</title>
      <description>
        <![CDATA[Regulatory and reimbursement challenges in Europe are leading an ever-increasing number of med tech companies to prioritize the U.S. market for the launch of their devices. However, certain technologies can reach European patients more quickly, presenting valuable opportunities with the EU, delegates heard at the LSI Europe ’25 conference in London this week.]]>
      </description>
      <guid>http://www.bioworld.com/articles/723736</guid>
      <pubDate>Thu, 11 Sep 2025 12:00:00 -0400</pubDate>
      <link>https://www.bioworld.com/articles/723736-opportunities-remain-in-the-eu-for-med-tech-despite-us-shift</link>
      <media:content url="https://www.bioworld.com/ext/resources/Stock-images/Geographic-regions/Europe/EU-flags-at-EC-building.webp?t=1735585376" type="image/jpeg" medium="image" fileSize="146760">
        <media:title type="plain">EU flags at European Commission building</media:title>
      </media:content>
    </item>
    <item>
      <title>FDA gives nod to Respiree wearable for home care</title>
      <description>
        <![CDATA[The U.S. FDA cleared Respiree Pte. Ltd.’s 510(k) for its RS-001 cardio-respiratory wearable that measures respiration and offers passive cardio-respiratory monitoring.]]>
      </description>
      <guid>http://www.bioworld.com/articles/723580</guid>
      <pubDate>Fri, 05 Sep 2025 12:00:00 -0400</pubDate>
      <link>https://www.bioworld.com/articles/723580-fda-gives-nod-to-respiree-wearable-for-home-care</link>
      <media:content url="https://www.bioworld.com/ext/resources/BMT-source/2025/Respiree-system-5sept25.webp?t=1757102252" type="image/jpeg" medium="image" fileSize="183808">
        <media:title type="plain">Respiree system</media:title>
      </media:content>
    </item>
    <item>
      <title>OIG presses for scrutiny of remote patient monitoring</title>
      <description>
        <![CDATA[The Office of Inspector General recently reported that billings for remote patient monitoring eclipsed the $500 million mark in 2024, but the agency stated that more scrutiny will be necessary going forward to keep waste, fraud and abuse at bay.]]>
      </description>
      <guid>http://www.bioworld.com/articles/723560</guid>
      <pubDate>Wed, 03 Sep 2025 12:00:00 -0400</pubDate>
      <link>https://www.bioworld.com/articles/723560-oig-presses-for-scrutiny-of-remote-patient-monitoring</link>
      <media:content url="https://www.bioworld.com/ext/resources/Stock-images/Regulatory/CMS-medicare-reimbursement.webp?t=1588869757" type="image/png" medium="image" fileSize="1528480">
        <media:title type="plain">Medicare puzzle</media:title>
      </media:content>
    </item>
    <item>
      <title>Greymind AI’s mental health platform offers 24/7 counseling</title>
      <description>
        <![CDATA[Patients often wait for a long time to see a mental health specialist to get the help they need, and Greymind AI’s mental health platform, Reboot AI, offers a stop-gap measure to provide structured early intervention with built-in escalation to human clinicians.]]>
      </description>
      <guid>http://www.bioworld.com/articles/723458</guid>
      <pubDate>Fri, 29 Aug 2025 12:00:00 -0400</pubDate>
      <link>https://www.bioworld.com/articles/723458-greymind-ais-mental-health-platform-offers-24-7-counseling</link>
      <media:content url="https://www.bioworld.com/ext/resources/Stock-images/Therapeutic-topics/Neurology/Mental-illness-art-concept.webp?t=1750710518" type="image/jpeg" medium="image" fileSize="333024">
        <media:title type="plain">Mental illness art concept</media:title>
      </media:content>
    </item>
    <item>
      <title>Aivis’ Qanti IHC uses AI to visualize biomarkers in cancer care</title>
      <description>
        <![CDATA[Lee Dae-hong founded Aivis Inc. in January 2021 as an AI-powered pathology software company, having led the development of the world’s first commercial under-display fingerprint recognition algorithm that was later incorporated into the Galaxy S10 and Galaxy A series of smartphones of Samsung Electronics Co. Ltd.]]>
      </description>
      <guid>http://www.bioworld.com/articles/723400</guid>
      <pubDate>Mon, 25 Aug 2025 12:00:00 -0400</pubDate>
      <link>https://www.bioworld.com/articles/723400-aivis-qanti-ihc-uses-ai-to-visualize-biomarkers-in-cancer-care</link>
      <media:content url="https://www.bioworld.com/ext/resources/BMT-source/2025/Aivis-25aug.webp?t=1756152833" type="image/jpeg" medium="image" fileSize="125578">
        <media:title type="plain">Aivis</media:title>
        <media:description type="plain">Aivis Qanti IHC. Credit: Aivis</media:description>
      </media:content>
    </item>
    <item>
      <title>Aclarion's Nociscan nearly doubles spine surgery success</title>
      <description>
        <![CDATA[Aclarion Inc.'s Nociscan, an AI-augmented platform that leverages MR spectroscopy to noninvasively identify the discs causing low-back pain, enables precise targeting of surgical intervention, resulting in 97% success. That’s roughly double the rate of 48% to 54% seen in conventional procedures for discogenic lower back pain, Aclarion CEO Brent Ness told BioWorld.]]>
      </description>
      <guid>http://www.bioworld.com/articles/723207</guid>
      <pubDate>Fri, 22 Aug 2025 12:00:00 -0400</pubDate>
      <link>https://www.bioworld.com/articles/723207-aclarions-nociscan-nearly-doubles-spine-surgery-success</link>
      <media:content url="https://www.bioworld.com/ext/resources/Stock-images/Therapeutic-topics/Musculoskeletal/Spine-orthopedics-digital.webp?t=1645135963" type="image/png" medium="image" fileSize="386472">
        <media:title type="plain">Digital spine concept art</media:title>
      </media:content>
    </item>
    <item>
      <title>FDA clears Artrya’s Salix AI coronary plaque module</title>
      <description>
        <![CDATA[The U.S. FDA has cleared Artrya Ltd.’s 510(k) for its Salix coronary plaque (SCP) module that is a bolt-on module to the company’s Salix coronary anatomy platform.]]>
      </description>
      <guid>http://www.bioworld.com/articles/723205</guid>
      <pubDate>Fri, 22 Aug 2025 12:00:00 -0400</pubDate>
      <link>https://www.bioworld.com/articles/723205-fda-clears-artryas-salix-ai-coronary-plaque-module</link>
      <media:content url="https://www.bioworld.com/ext/resources/BMT-source/2025/Artryas-Salix-22aug25.webp?t=1755894201" type="image/jpeg" medium="image" fileSize="132134">
        <media:title type="plain">Artryas Salix</media:title>
        <media:description type="plain">Artrya Ltd. Salix coronary anatomy software analyzes coronary computed tomography angiogram scans via AI to diagnose coronary artery disease. Credit: Artrya.</media:description>
      </media:content>
    </item>
    <item>
      <title>Signos adds AI to CGM to drive weight loss</title>
      <description>
        <![CDATA[Signos Inc. landed U.S. FDA clearance for its over-the-counter glucose monitoring system, which combines Dexcom Inc.'s non-prescription Stelo continuous glucose monitor with an AI-powered platform focused on weight management and metabolism. The sensor transmits glucose readings to a smartphone app that interprets the data, provides guidance for healthy habits and educates the user. ]]>
      </description>
      <guid>http://www.bioworld.com/articles/723195</guid>
      <pubDate>Thu, 21 Aug 2025 12:00:00 -0400</pubDate>
      <link>https://www.bioworld.com/articles/723195-signos-adds-ai-to-cgm-to-drive-weight-loss</link>
      <media:content url="https://www.bioworld.com/ext/resources/BMT-source/2025/stelo-21aug25.webp?t=1755813087" type="image/jpeg" medium="image" fileSize="5328">
        <media:title type="plain">Signots Stelo</media:title>
        <media:description type="plain">Signos Stelo CGM. Credit: Courtesy Signos Inc.</media:description>
      </media:content>
    </item>
    <item>
      <title>Apple reintroduces pulseox via software update</title>
      <description>
        <![CDATA[Some Apple Watch users will be able to monitor their blood oxygen levels through their iPhone, thanks to a software update the company planned to issue Aug. 14. The Cupertino, Calif.-based company pulled the feature from its watches in the U.S. in 2024, following a patent dispute with Masimo Corp., of Irvine, Calif., that threatened an import ban.]]>
      </description>
      <guid>http://www.bioworld.com/articles/722858</guid>
      <pubDate>Thu, 14 Aug 2025 12:00:00 -0400</pubDate>
      <link>https://www.bioworld.com/articles/722858-apple-reintroduces-pulseox-via-software-update</link>
      <media:content url="https://www.bioworld.com/ext/resources/BMT-source/2025/apple-watch-pulseox-14aut25.webp?t=1755209042" type="image/jpeg" medium="image" fileSize="134041">
        <media:title type="plain">Apple Watch pulseox</media:title>
        <media:description type="plain">Credit: Kaboompics.com</media:description>
      </media:content>
    </item>
    <item>
      <title>Research details new AI-enhanced 3D ultrasound imaging method</title>
      <description>
        <![CDATA[A research team from Pusan National University has developed a novel deep learning model coined Moglo-Net, designed to enable three-dimensional reconstruction of images from hand-held ultrasound procedures.]]>
      </description>
      <guid>http://www.bioworld.com/articles/722819</guid>
      <pubDate>Mon, 11 Aug 2025 12:00:00 -0400</pubDate>
      <link>https://www.bioworld.com/articles/722819-research-details-new-ai-enhanced-3d-ultrasound-imaging-method</link>
      <media:content url="https://www.bioworld.com/ext/resources/BMT-source/2025/PNU-AI-ultrasound-11aug25.webp?t=1754949023" type="image/jpeg" medium="image" fileSize="263692">
        <media:title type="plain">PNU AI ultrasound</media:title>
        <media:description type="plain">Moglo-Net tracks the motion of the ultrasound transducer using tissue speckle data without the need for external sensors, creating a clear 3D ultrasound volume for accurate visualization of bodily structures, enabling more efficient and safe medical treatments. Credit: PNU</media:description>
      </media:content>
    </item>
    <item>
      <title>CMS takes aim at skin substitutes, telehealth in 2026 doc fee draft</title>
      <description>
        <![CDATA[The U.S. Centers for Medicare & Medicaid Services (CMS) has pulled off the gloves when it comes to spending on skin substitutes in the draft Medicare physician fee schedule for 2026, proposing a payment methodology that would slash spending by 90%. However, the doc fee draft also proposes to simplify the process by which telehealth coverage is provided for a physician service, a move that may significantly expand the types of services that can be handled without an in-office visit.]]>
      </description>
      <guid>http://www.bioworld.com/articles/721952</guid>
      <pubDate>Tue, 15 Jul 2025 12:00:00 -0400</pubDate>
      <link>https://www.bioworld.com/articles/721952-cms-takes-aim-at-skin-substitutes-telehealth-in-2026-doc-fee-draft</link>
      <media:content url="https://www.bioworld.com/ext/resources/Stock-images/Devices/digital-health-telehealth-phone-doctor.webp?t=1595547749" type="image/png" medium="image" fileSize="743872">
        <media:title type="plain">Telehealth illustration</media:title>
      </media:content>
    </item>
    <item>
      <title>Lunit, Microsoft to codevelop cloud-based clinical AI solutions</title>
      <description>
        <![CDATA[Lunit Inc. reported a new collaboration with Microsoft Corp. July 2 to jointly develop medical AI programs accessible on Microsoft’s Azure cloud platform.]]>
      </description>
      <guid>http://www.bioworld.com/articles/721647</guid>
      <pubDate>Thu, 03 Jul 2025 12:00:00 -0400</pubDate>
      <link>https://www.bioworld.com/articles/721647-lunit-microsoft-to-codevelop-cloud-based-clinical-ai-solutions</link>
      <media:content url="https://www.bioworld.com/ext/resources/BMT-source/2025/Lunit-10apr25.webp?t=1751573138" type="image/jpeg" medium="image" fileSize="492132">
        <media:title type="plain">Lunit</media:title>
      </media:content>
    </item>
    <item>
      <title>MHRA tackles risk classification for digital mental health tech</title>
      <description>
        <![CDATA[The U.K. Medicines and Healthcare Products Regulator Agency dropped a guidance for digital mental health technologies that clarifies several key points, such as when the DMHT qualifies as software as a medical device.]]>
      </description>
      <guid>http://www.bioworld.com/articles/721644</guid>
      <pubDate>Thu, 03 Jul 2025 12:00:00 -0400</pubDate>
      <link>https://www.bioworld.com/articles/721644-mhra-tackles-risk-classification-for-digital-mental-health-tech</link>
      <media:content url="https://www.bioworld.com/ext/resources/BMT-source/2024/thumb/mhra-logo.webp?t=1707169524" type="image/jpeg" medium="image" fileSize="26418">
        <media:title type="plain">MHRA logo</media:title>
      </media:content>
    </item>
    <item>
      <title>Reset Moves to promote well-being in children with neurodivergence</title>
      <description>
        <![CDATA[Focused on promoting well-being amongst children with neurodivergence, Reset Moves Pty Ltd. created app-based games to help children not only focus with greater clarity, but also to better help them re-engage in certain settings.]]>
      </description>
      <guid>http://www.bioworld.com/articles/721111</guid>
      <pubDate>Mon, 16 Jun 2025 12:00:00 -0400</pubDate>
      <link>https://www.bioworld.com/articles/721111-reset-moves-to-promote-well-being-in-children-with-neurodivergence</link>
      <media:content url="https://www.bioworld.com/ext/resources/BMT-source/2025/Reset-moves-action-shot-2-16june25.webp?t=1750107418" type="image/jpeg" medium="image" fileSize="305012">
        <media:title type="plain">Reset Moves action shot</media:title>
        <media:description type="plain">Keeping kids active is one of Reset Moves’ priorities. Credit: Reset Moves</media:description>
      </media:content>
    </item>
    <item>
      <title>Hinge Health rings NYSE bell as IPO raises $437M</title>
      <description>
        <![CDATA[Hinge Health Inc.’s flexibility produced big rewards as the digital therapy company for physical rehabilitation finally began trading on the NYSE under the symbol HNGE on May 22 after delaying its IPO twice. Hinge co-founders Daniel Perez and Gabriel Mecklenburg rang the opening bell for the stock exchange to celebrate the offering’s $437 million haul.]]>
      </description>
      <guid>http://www.bioworld.com/articles/720269</guid>
      <pubDate>Thu, 22 May 2025 12:00:00 -0400</pubDate>
      <link>https://www.bioworld.com/articles/720269-hinge-health-rings-nyse-bell-as-ipo-raises-437m</link>
      <media:content url="https://www.bioworld.com/ext/resources/Stock-images/Money/Businessman-and-IPO-virtual-screen.webp?t=1717791671" type="image/jpeg" medium="image" fileSize="332138">
        <media:title type="plain">Businessman and IPO virtual screen</media:title>
      </media:content>
    </item>
  </channel>
</rss>
